Neutropenia in Medical News
Navigation Links
Neutropenia in Medical News
... absolute neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in ... or hemorrhage
Sepsis occurring during neutropenia has resulted in discontinuation of treatment and ... 5 percent (DOXIL vs topotecan, respectively) were neutropenia (12 percent vs 76 percent) and anemia (6 percent ...
... and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and Grade 3 or 4 platelet ... 9.5% of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ... equal to age 70, 7% and 5.5% experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ...
... adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia ... adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). ... (NCI Grades 3/4) lab abnormalities - including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ...
... quite favorable. There were four cases of febrile neutropenia with eight patients requiring a dose-modification ... mucositis (14 percent), anemia (12 percent), and neutropenia (11 percent). Immunochemotherapy ... in the FC arm. While FCR was found to cause more neutropenia (33.6 percent versus 20.9 percent) and leukopenia ...
... NSCLC were anemia (8 vs 7); leukopenia (5 vs 28); neutropenia (5 vs 40); thrombocytopenia (2 vs 1); ALT elevation (3 vs 1); febrile neutropenia (2 vs 13); infection without neutropenia (6 vs 4); infection/febrile neutropenia - other ...
... NSCLC were anemia (8 vs 7); leukopenia (5 vs 28); neutropenia (5 vs 40); thrombocytopenia (2 vs 1); ALT elevation (3 vs 1); febrile neutropenia (2 vs 13); infection without neutropenia (6 vs 4); infection/febrile neutropenia -- other ...
... with hematologic malignancies with prolonged neutropenia from chemotherapy. In October 2006, the FDA ... for AML or MDS expected to result in prolonged neutropenia and HSCT recipients who are undergoing high-dose ... refractory OPC patients included fever (13%) and neutropenia (10%). Coadministration with the CYP3A4 ...
... studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained ... required no pre-treatment with corticosteroids and shown no evidence of neutropenia in patients to date. About NKTR-105 NKTR-105 is a novel ...
... (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal ... 1 episode of ¿Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
... with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ... than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
... of the individual agents in the combination, including thrombocytopenia, neutropenia and peripheral neuropathy. About Multiple Myeloma Multiple myeloma is ... 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
... or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with ... hypokalemia (31.3%). Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed ...
... report evidence of neuropathy in 30 percent of patients, including severe neuropathy (Grade 3/4) in almost 2 percent of patients.i neutropenia was the main hematologic toxicity. In contrast with picoplatin monotherapy in previous studies, thrombocytopenia was less severe and less frequent ...
... Each year, 60,000 cancer patients are hospitalized for chemotherapy-induced neutropenia, and a patient dies every two hours from this complication. neutropenia also can potentially disrupt chemotherapy treatment, including both dose delays and dose reductions. Studies show that for certain types of cancer, ...
... be used with caution in patients with known cardiovascular disease, and conditions that would predispose patients to hypotension. Leukopenia, neutropenia and Agranulocytosis have been reported with antipsychotics, including risperidone. Patients with a pre-existing low white blood cell count (WBC) or ...
... be used with caution in patients with known cardiovascular disease, and conditions that would predispose patients to hypotension. Leukopenia, neutropenia and Agranulocytosis have been reported with antipsychotics, including risperidone. Patients with a pre-existing low white blood cell count (WBC) or ...
... In Phase III unresectable or metastatic GIST trials (400 mg/day; 800 mg/day), severe (NCI Grades 3/4/5) lab abnormalities - including neutropenia (3%; 4%) and anemia (5%; 6%) - and severe adverse reactions (NCI Grades 3/4/5), including severe fluid retention (9% to 13%) and edema (9%; 13%), ...
... percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 percent), arthralgia (22 ...
... percent were treated for clinical hypothyroidism. Dose modifications were required in 25 percent of patients, most commonly for anemia, neutropenia and weight loss. Therapy was discontinued prematurely in two percent of the patients. About Hepatitis C Hepatitis C is a serious ...
... patients in Study 1, and monthly monitoring is recommended. There have been postmarketing reports of cytopenias (including agranulocytosis, neutropenia and thrombocytopenia) in patients treated with EXJADE. Some of these patients died. The relationship of these episodes to treatment with EXJADE is ...
... child while receiving treatment with Dacogen(R) and for two months afterwards. The most commonly occurring adverse reactions with Dacogen(R) include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and ...
... billion by the year 2012. Growth will also be encouraged by the recent success of commercialized products in new therapeutic applications such as neutropenia prevention and treatment. San Jose, CA (PRWEB) November 10, 2008 -- Age-related conditions such as Alzheimer's disease, ...
Amgen Highlights Data to Be Presented at ASCO
... Neulasta (R) (pegfilgrastim) neutropenia is a common and potentially dangerous side effect ... mortality in cancer patients experiencing febrile neutropenia (neutropenia with fever) based on clinical ... in patients with cancer experiencing febrile neutropenia Lead Author: Barron R Abstract ...... and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and Grade 3 or 4 platelet ... 9.5% of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ... equal to age 70, 7% and 5.5% experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ...
... adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia ... adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). ... (NCI Grades 3/4) lab abnormalities - including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ...
Scientists identify new congenital neutropenia syndrome and causative gene mutation
... a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack ... in this newly defined group of severe congenital neutropenia patients," said Christoph Klein, M.D., Ph.D., ... lead author of the study. Severe congenital neutropenia (SCN) is a rare disorder, with an incidence of ...Novel treatments show improvements in survival and response rates for leukemia and lymphoma
... favorable. There were four cases of febrile neutropenia with eight patients requiring a dose-modification ... mucositis (14 percent), anemia (12 percent), and neutropenia (11 percent). Immunochemotherapy With ... in the FC arm. While FCR was found to cause more neutropenia (33.6 percent versus 20.9 percent) and leukopenia ...... quite favorable. There were four cases of febrile neutropenia with eight patients requiring a dose-modification ... mucositis (14 percent), anemia (12 percent), and neutropenia (11 percent). Immunochemotherapy ... in the FC arm. While FCR was found to cause more neutropenia (33.6 percent versus 20.9 percent) and leukopenia ...
... NSCLC were anemia (8 vs 7); leukopenia (5 vs 28); neutropenia (5 vs 40); thrombocytopenia (2 vs 1); ALT elevation (3 vs 1); febrile neutropenia (2 vs 13); infection without neutropenia (6 vs 4); infection/febrile neutropenia - other ...
... NSCLC were anemia (8 vs 7); leukopenia (5 vs 28); neutropenia (5 vs 40); thrombocytopenia (2 vs 1); ALT elevation (3 vs 1); febrile neutropenia (2 vs 13); infection without neutropenia (6 vs 4); infection/febrile neutropenia -- other ...
... with hematologic malignancies with prolonged neutropenia from chemotherapy. In October 2006, the FDA ... for AML or MDS expected to result in prolonged neutropenia and HSCT recipients who are undergoing high-dose ... refractory OPC patients included fever (13%) and neutropenia (10%). Coadministration with the CYP3A4 ...
Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
... The most common grade 3/4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3/4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3/4 infections had ...... studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained ... required no pre-treatment with corticosteroids and shown no evidence of neutropenia in patients to date. About NKTR-105 NKTR-105 is a novel ...
Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
... arm, p = 0.003). Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting ... arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia and numerically more severe cardiac events (5 vs. 2) with only 1 ...Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
... 2 studies for Myelodysplastic Syndrome (MDS) and Chemotherapy Induced neutropenia (CIN). The company also plans to initiate a Phase 2 Study in Severe Chronic Idiopathic neutropenia (SCIN) this year. The company will pursue a corporate partnership for the ...... (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal ... 1 episode of ¿Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
InterMune Reports Results from Triple Combination Study of ITMN-191
... by the investigator to be unrelated to ITMN-191. The other two were neutropenia and indirect bilirubin elevation. neutropenia occurred with a similar pattern, frequency and severity in the placebo and ...Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
... respectively, were: Hematological reactions including neutropenia (77% versus 38%, with febrile neutropenia occurring in 8% of the cases and sepsis in 1% of the cases), leucopenia ...... with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ... than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
... of the individual agents in the combination, including thrombocytopenia, neutropenia and peripheral neuropathy. About Multiple Myeloma Multiple myeloma is ... 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
JCI table of contents: Feb. 21, 2008
... in patients with too few white blood cells may lead to leukemia neutropenia is a disease characterized by low numbers of white blood cells called ... infections. A high proportion of patients who have severe congenital neutropenia have mutations in their CSFR3 gene, which is responsible for making the ...St. Jude Finds Risk Factors for Severe RSV Infection in Immunocompromised Children
... is not a risk factor for lower respiratory track infection, Gaur said. neutropenia is an abnormally low level of neutrophils, immune system cells that engulf ... study shows that for RSV, which is a viral infection, lymphopenia and not neutropenia is what identifies children at risk. Previous studies have shown that ...St. Jude finds risk factors for severe RSV infection in immunocompromised children
... is not a risk factor for lower respiratory track infection, Gaur said. neutropenia is an abnormally low level of neutrophils, immune system cells that engulf ... study shows that for RSV, which is a viral infection, lymphopenia and not neutropenia is what identifies children at risk. Previous studies have shown that ...... or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with ... hypokalemia (31.3%). Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed ...
Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications
... of therapy. In these patients, SEROQUEL should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL should be discontinued in any patient if the absolute neutrophil count is 1000/mm3. Tardive ...New survey highlights growing concern about risk of infection in cancer patients
... Each year, 60,000 cancer patients are hospitalized for chemotherapy-induced neutropenia, and a patient dies every two hours from this complication. neutropenia also can potentially disrupt chemotherapy treatment, including both dose delays and dose reductions. Studies show that for certain types of cancer, ...... report evidence of neuropathy in 30 percent of patients, including severe neuropathy (Grade 3/4) in almost 2 percent of patients.i neutropenia was the main hematologic toxicity. In contrast with picoplatin monotherapy in previous studies, thrombocytopenia was less severe and less frequent ...
... Each year, 60,000 cancer patients are hospitalized for chemotherapy-induced neutropenia, and a patient dies every two hours from this complication. neutropenia also can potentially disrupt chemotherapy treatment, including both dose delays and dose reductions. Studies show that for certain types of cancer, ...
... be used with caution in patients with known cardiovascular disease, and conditions that would predispose patients to hypotension. Leukopenia, neutropenia and Agranulocytosis have been reported with antipsychotics, including risperidone. Patients with a pre-existing low white blood cell count (WBC) or ...
... be used with caution in patients with known cardiovascular disease, and conditions that would predispose patients to hypotension. Leukopenia, neutropenia and Agranulocytosis have been reported with antipsychotics, including risperidone. Patients with a pre-existing low white blood cell count (WBC) or ...
FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications
... these patients, SEROQUEL XR and SEROQUEL should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR and SEROQUEL should be discontinued in any patient if the absolute neutrophil count is < 1000/mm3. ...Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
... control rate was 47 percent in the 77 evaluable patients. The most common side effects observed were hematologic and included thrombocytopenia, neutropenia and anemia. No grade 3 or 4 neurotoxicity or nephrotoxicity and no treatment-related deaths occurred in the study. "The publication of these ...FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications
... these patients, SEROQUEL XR and SEROQUEL should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR and SEROQUEL should be discontinued in any patient if the absolute neutrophil count is < 1000/mm3. ...FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
... therapy. In these patients, SEROQUEL XR should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is < 1000/mm3. Tardive ...... In Phase III unresectable or metastatic GIST trials (400 mg/day; 800 mg/day), severe (NCI Grades 3/4/5) lab abnormalities - including neutropenia (3%; 4%) and anemia (5%; 6%) - and severe adverse reactions (NCI Grades 3/4/5), including severe fluid retention (9% to 13%) and edema (9%; 13%), ...
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
... therapy. In these patients, SEROQUEL XR should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is < 1000/cubic mm. ...... percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 percent), arthralgia (22 ...
... percent were treated for clinical hypothyroidism. Dose modifications were required in 25 percent of patients, most commonly for anemia, neutropenia and weight loss. Therapy was discontinued prematurely in two percent of the patients. About Hepatitis C Hepatitis C is a serious ...
... patients in Study 1, and monthly monitoring is recommended. There have been postmarketing reports of cytopenias (including agranulocytosis, neutropenia and thrombocytopenia) in patients treated with EXJADE. Some of these patients died. The relationship of these episodes to treatment with EXJADE is ...
... child while receiving treatment with Dacogen(R) and for two months afterwards. The most commonly occurring adverse reactions with Dacogen(R) include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and ...
... billion by the year 2012. Growth will also be encouraged by the recent success of commercialized products in new therapeutic applications such as neutropenia prevention and treatment. San Jose, CA (PRWEB) November 10, 2008 -- Age-related conditions such as Alzheimer's disease, ...
Other ContentspostoperativepostoperativepostoperativepostoperativepostpartumpostpartumhydroxidehydroxidehydroxidepotassiumpotassiumpotassiumpotassiumpotassiumpotassiumpotassiumpreeclampsiapreeclampsiapremenstrualpremenstrualpotatopotatopotatopotatopotatoOther TagspayseFilmrevampgradesCatoCatoCatoCatovievievievievierejectsOther Tagsstone 2stone 3stone 4baked 2baked 3likelihood 2likelihood 3likelihood 4likelihood 5likelihood 6likelihood 7likelihood 8likelihood 9likelihood 10transcripts 2
(Date:12/16/2009)... 3 BIO-key International, Inc. (OTC ... public safety and finger-based biometric identification solutions, ... at a Special Shareholder Meeting held today ... Enforcement Division to Interact911 Mobile Systems Inc. ... in favor and 1.2% were opposed. ,, ...
(Date:12/16/2009)... National Instruments (Nasdaq: NATI ... control, and DENSO Robotics, a leader and ... today announced their collaboration to integrate NI ... arms. The collaboration increases productivity and performance ... applications. In today,s trend toward high-mix, low-volume ...
(Date:12/16/2009)... FALLS CHURCH, Va., Dec. 9 ... today that the American Association for Laboratory ... Electrotechnical Commission (ISO/IEC) 17025:2005 accreditation to the ... the CSC Identity Labs located in Fairmont, ... biometrics test laboratory in the world to ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2First national study to examine rock climbing related injuries 52299 1First national study to examine rock climbing related injuries 52299 2Tires made from trees better cheaper more fuel efficient 9304 1Tires made from trees better cheaper more fuel efficient 9304 2Lumenis Worlds Largest Medical Laser Company Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 52297 1Lumenis Worlds Largest Medical Laser Company Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 52297 2Lumenis Worlds Largest Medical Laser Company Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 52297 3Lumenis Worlds Largest Medical Laser Company Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 52297 4(Date:12/16/2009)... never felt so good for "The Biggest Loser" Danny ... continuing to make smart choices everyday to help him ... choice that is an important part of living well. ... glass of milk has nine essential nutrients like protein ... pressure, and calcium and vitamin D for strong bones. ...
(Date:12/16/2009)... -- For wounded U.S. servicemen and women ... D.C., the holidays can be a particularly difficult time. ... rely more than ever on the healing power of ... home just got easier for Walter Reed patients as ... will provide hundreds of minutes of holiday talk time ...
(Date:12/16/2009)... a result of C3: Colorectal Cancer Coalition,s advocacy efforts, ... program is included in the final Fiscal Year 2010 ... program will research cancers, like colorectal cancer, that are ... cancer research programs run by the U.S. Army Medical ... million in funding for this new cancer research program ...
(Date:12/16/2009)... deadly, attack is long-term goal, researchers say , , ... a tool to predict whether a patient will suffer ... stroke. , "This is an important new tool because ... stroke soon after a first stroke are more likely ... of Massachusetts General Hospital and Harvard Medical School, said ...
(Date:12/16/2009)... it plays a role in reducing inflammation in the ... gene variant that plays a role in inflammation seems ... well as adults who smoke. , Researchers also found ... gene had a lower risk of developing chronic obstructive ... by smoking. , "The gene seems to be protective ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |